Nombre del producto:3-Isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-ol

IUPAC Name:9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol

CAS:3466-75-9
Fórmula molecular:C19H29NO3
Pureza:95%
Número de catálogo:CM228706
Peso molecular:319.45

Unidad de embalaje Stock disponible Precio($) Cantidad
CM228706-1g in stock ƈŌŤ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :3466-75-9
Fórmula molecular:C19H29NO3
Punto de fusión:-
Código de sonrisas:OC(C(CC(C)C)C1)CC2N1CCC3=C2C=C(OC)C(OC)=C3
Densidad:
Número de catálogo:CM228706
Peso molecular:319.45
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Category Infos

Piperidines
Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
Piperidine,Piperidine Price
if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.
Tetrahydroisoquinolines
Tetrahydroisoquinoline is an organic compound with the chemical formula C9H11N. It is classified as a secondary amine, obtained from isoquinoline by hydrogenation. The tetrahydroisoquinoline moiety forms the backbone of several natural, synthetic and semi-synthetic drugs approved for the treatment of cancer, pain, gout and various neurodegenerative diseases.

Column Infos

Valbenazine
Neurocrine Biosciences announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (Valbenazine) capsules when used for the long-term treatment of adults with chorea associated with Huntington's disease (HD). Interim data suggest one-capsule, once-daily INGREZZA improved chorea at the first evaluation at Week 2 with sustained efficacy through Week 50. INGREZZA® (Valbenazine) is the only one-capsule, once-daily selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by FDA for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products